This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow An author's correction has been published
Right arrow An author's correction has been published
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lam, P. Y. P.
Right arrow Articles by Roussel, M. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lam, P. Y. P.
Right arrow Articles by Roussel, M. F.

 Previous Article  |  Next Article 

Molecular and Cellular Biology, January 1999, p. 594-601, Vol. 19, No. 1
0270-7306/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

The Oncogenic Potential of the Pax3-FKHR Fusion Protein Requires the Pax3 Homeodomain Recognition Helix but Not the Pax3 Paired-Box DNA Binding Domain

Paula Y. P. Lam,1,dagger Jack E. Sublett,2 Andrew D. Hollenbach,3 and Martine F. Roussel4,*

Departments of Experimental Oncology,1 Developmental Neurobiology,2 Genetics,3 and Tumor Cell Biology,4 St. Jude Children's Research Hospital, Memphis, Tennessee 38105

Received 4 February 1998/Returned for modification 17 March 1998/Accepted 1 October 1998

The chimeric transcription factor Pax3-FKHR, produced by the t(2;13)(q35;q14) chromosomal translocation in alveolar rhabdomyosarcoma, consists of the two Pax3 DNA binding domains (paired box and homeodomain) fused to the C-terminal forkhead (FKHR) sequences that contain a potent transcriptional activation domain. To determine which of these domains are required for cellular transformation, Pax3, Pax3-FKHR, and selected mutants were retrovirally expressed in NIH 3T3 cells and evaluated for their capacity to promote anchorage-independent cell growth. Mutational analysis revealed that both the third alpha -helix of the homeodomain and a small region of the FKHR transactivation domain are absolutely required for efficient transformation by the Pax3-FKHR fusion protein. Surprisingly, point mutations in the paired domain that abrogate sequence-specific DNA binding retained transformation potential equivalent to that of the wild-type protein. This finding suggests that DNA binding mediated through the Pax3 paired box is not required for transformation. Our results demonstrate that the integrity of the Pax3 homeodomain recognition helix and the FKHR transactivation domain is necessary for efficient cellular transformation by the Pax3-FKHR fusion protein.

* Corresponding author. Mailing address: Department of Tumor Cell Biology, 332 North Lauderdale, Memphis, TN 38105. Phone: (901) 495-3481. Fax: (901) 495-2381. E-mail: martine.roussel{at}stjude.org.

dagger Present address: Molecular Neurogenetics Unit, Departments of Neurology and Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02129.

Molecular and Cellular Biology, January 1999, p. 594-601, Vol. 19, No. 1
0270-7306/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Wang, Q., Kumar, S., Slevin, M., Kumar, P. (2006). Functional Analysis of Alternative Isoforms of the Transcription Factor PAX3 in Melanocytes In vitro.. Cancer Res. 66: 8574-8580 [Abstract] [Full Text]  
  • Nabarro, S., Himoudi, N., Papanastasiou, A., Gilmour, K., Gibson, S., Sebire, N., Thrasher, A., Blundell, M. P., Hubank, M., Canderan, G., Anderson, J. (2005). Coordinated oncogenic transformation and inhibition of host immune responses by the PAX3-FKHR fusion oncoprotein. JEM 202: 1399-1410 [Abstract] [Full Text]  
  • Bois, P. R.J., Izeradjene, K., Houghton, P. J., Cleveland, J. L., Houghton, J. A., Grosveld, G. C. (2005). FOXO1a acts as a selective tumor suppressor in alveolar rhabdomyosarcoma. JCB 170: 903-912 [Abstract] [Full Text]  
  • Kortylewski, M., Feld, F., Kruger, K.-D., Bahrenberg, G., Roth, R. A., Joost, H.-G., Heinrich, P. C., Behrmann, I., Barthel, A. (2003). Akt Modulates STAT3-mediated Gene Expression through a FKHR (FOXO1a)-dependent Mechanism. J. Biol. Chem. 278: 5242-5249 [Abstract] [Full Text]  
  • So, C. W., Cleary, M. L. (2003). Common mechanism for oncogenic activation of MLL by forkhead family proteins. Blood 101: 633-639 [Abstract] [Full Text]  
  • Zhang, L., Wang, C. (2003). PAX3-FKHR Transformation Increases 26 S Proteasome-dependent Degradation of p27Kip1, a Potential Role for Elevated Skp2 Expression. J. Biol. Chem. 278: 27-36 [Abstract] [Full Text]  
  • Lagutina, I., Conway, S. J., Sublett, J., Grosveld, G. C. (2002). Pax3-FKHR Knock-In Mice Show Developmental Aberrations but Do Not Develop Tumors. Mol. Cell. Biol. 22: 7204-7216 [Abstract] [Full Text]  
  • So, C. W., Cleary, M. L. (2002). MLL-AFX Requires the Transcriptional Effector Domains of AFX To Transform Myeloid Progenitors and Transdominantly Interfere with Forkhead Protein Function. Mol. Cell. Biol. 22: 6542-6552 [Abstract] [Full Text]  
  • Barr, F. G., Qualman, S. J., Macris, M. H., Melnyk, N., Lawlor, E. R., Strzelecki, D. M., Triche, T. J., Bridge, J. A., Sorensen, P. H. B. (2002). Genetic Heterogeneity in the Alveolar Rhabdomyosarcoma Subset without Typical Gene Fusions. Cancer Res. 62: 4704-4710 [Abstract] [Full Text]  
  • Hollenbach, A. D., McPherson, C. J., Mientjes, E. J., Iyengar, R., Grosveld, G. (2002). Daxx and histone deacetylase II associate with chromatin through an interaction with core histones and the chromatin-associated protein Dek. J. Cell Sci. 115: 3319-3330 [Abstract] [Full Text]  
  • Buijs, A., van Rompaey, L., Molijn, A. C., Davis, J. N., Vertegaal, A. C. O., Potter, M. D., Adams, C., van Baal, S., Zwarthoff, E. C., Roussel, M. F., Grosveld, G. C. (2000). The MN1-TEL Fusion Protein, Encoded by the Translocation (12;22)(p13;q11) in Myeloid Leukemia, Is a Transcription Factor with Transforming Activity. Mol. Cell. Biol. 20: 9281-9293 [Abstract] [Full Text]  
  • Cao, Y., Wang, C. (2000). The COOH-terminal Transactivation Domain Plays a Key Role in Regulating the in Vitro and in Vivo Function of Pax3 Homeodomain. J. Biol. Chem. 275: 9854-9862 [Abstract] [Full Text]  
  • Bosilevac, J. M., Olsen, R. J., Bridge, J. A., Hinrichs, S. H. (1999). Tumor Cell Viability in Clear Cell Sarcoma Requires DNA Binding Activity of the EWS/ATF1 Fusion Protein. J. Biol. Chem. 274: 34811-34818 [Abstract] [Full Text]  
  • Kempf, B. E., Vogt, P. K. (1999). A Genetic Analysis of PAX3-FKHR, the Oncogene of Alveolar Rhabdomyosarcoma. Cell Growth Differ. 10: 813-818 [Abstract] [Full Text]  
  • Khan, J., Bittner, M. L., Saal, L. H., Teichmann, U., Azorsa, D. O., Gooden, G. C., Pavan, W. J., Trent, J. M., Meltzer, P. S. (1999). cDNA microarrays detect activation of a myogenic transcription program by the PAX3-FKHR fusion oncogene. Proc. Natl. Acad. Sci. USA 96: 13264-13269 [Abstract] [Full Text]  
  • Galibert, M.-D., Yavuzer, U., Dexter, T. J., Goding, C. R. (1999). Pax3 and Regulation of the Melanocyte-specific Tyrosinase-related Protein-1 Promoter. J. Biol. Chem. 274: 26894-26900 [Abstract] [Full Text]  
  • Planque, N., Leconte, L., Coquelle, F. M., Martin, P., Saule, S. (2001). Specific Pax-6/Microphthalmia Transcription Factor Interactions Involve Their DNA-binding Domains and Inhibit Transcriptional Properties of Both Proteins. J. Biol. Chem. 276: 29330-29337 [Abstract] [Full Text]  
  • Mayanil, C. S. K., George, D., Freilich, L., Miljan, E. J., Mania-Farnell, B., McLone, D. G., Bremer, E. G. (2001). Microarray Analysis Detects Novel Pax3 Downstream Target Genes. J. Biol. Chem. 276: 49299-49309 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»